Chren Mary-Margaret, Sahay Anju P, Sands Laura P, Maddock Leah, Lindquist Karla, Bertenthal Daniel, Bacchetti Peter
Dermatology Service, Research Enhancement Award Program of the Health Services Research and Development Service, Department of Veterans Affairs, San Francisco Veterans Affairs Medical Center, San Francisco, California 94121, USA.
Med Care. 2004 Oct;42(10):1019-26. doi: 10.1097/00005650-200410000-00011.
Nonmelanoma skin cancer is the most common malignancy. Multiple therapies prevent recurrence but vary widely in cost. The most common therapies are local destruction, excision, and Mohs surgery (histologically guided tumor removal). Clinical variables that may affect treatment choices can be identified, but little is known about how clinicians choose among therapies.
The objective of this study was to learn if variations exist in the treatment of nonmelanoma skin cancer in different practice settings.
Prospective cohort study.
Subjects consisted of consecutive patients with nonmelanoma skin cancer at a university-affiliated private dermatology practice and the dermatology clinic at the nearby affiliated Veterans Affairs (VA) medical center.
We studied data from medical records and patient surveys.
Overall, 1777 nonrecurrent nonmelanoma skin cancers were diagnosed in 1375 patients. Compared with the VA site, patients at the private site were younger, more likely to be female, and less likely to be poor, and their tumors were smaller and less likely to be on visible areas of the body. Treatments varied between the 2 sites (P <0.001). The proportions of tumors treated at the private and VA sites, respectively, were 23% and 19% for destruction, 25% and 48% for excision, and 37% and 25% for Mohs surgery. In multiple clinical subgroups, Mohs surgery was more likely to be performed at the private site than at the VA. Moreover, in multivariable models controlling for clinical features that may have affected treatment choice, tumors at the private site were more likely than tumors at the VA to be treated with Mohs surgery (odds ratio, 2.39; 95% confidence interval, 1.54-3.70).
Care for nonmelanoma skin cancer varied at 2 academic practice sites that are near each other and that share some clinician staff. These findings raise questions not only about overuse or underuse of procedures at the 2 sites, but also about systematic differences in patient preferences and/or physician incentives in prepaid and fee-for-service settings.
非黑色素瘤皮肤癌是最常见的恶性肿瘤。多种治疗方法可预防复发,但成本差异很大。最常见的治疗方法是局部破坏、切除和莫氏手术(组织学引导下的肿瘤切除)。可以确定可能影响治疗选择的临床变量,但对于临床医生如何在多种治疗方法中做出选择知之甚少。
本研究的目的是了解不同医疗机构中,非黑色素瘤皮肤癌的治疗方法是否存在差异。
前瞻性队列研究。
研究对象包括一所大学附属私立皮肤科诊所及附近附属退伍军人事务部(VA)医疗中心皮肤科诊所中,连续就诊的非黑色素瘤皮肤癌患者。
我们研究了病历和患者调查数据。
总体而言,1375例患者共诊断出1777例非复发性非黑色素瘤皮肤癌。与VA医疗中心相比,私立诊所的患者更年轻,女性比例更高,贫困率更低,肿瘤更小,且位于身体可见部位的可能性更小。两个医疗机构的治疗方法存在差异(P<0.001)。私立诊所和VA医疗中心接受局部破坏治疗的肿瘤比例分别为23%和19%,切除治疗的比例分别为25%和48%,莫氏手术治疗的比例分别为37%和25%。在多个临床亚组中,私立诊所比VA医疗中心更有可能进行莫氏手术。此外,在控制了可能影响治疗选择的临床特征的多变量模型中,私立诊所的肿瘤比VA医疗中心的肿瘤更有可能接受莫氏手术治疗(优势比为2.39;95%置信区间为1.54-3.70)。
两所相邻且有部分临床医护人员共享的学术医疗机构,对非黑色素瘤皮肤癌的治疗存在差异。这些发现不仅引发了关于两所医疗机构治疗方法过度使用或使用不足的问题,还引发了关于预付制和按服务收费模式下患者偏好和/或医生激励机制的系统性差异的问题。